Anthracyclines are some of the most powerful agents available for the treatment of breast cancer and are frequently used in the adjuvant setting. However, anthracyclines are associated with severe adverse effects, such as cardiac toxicity and bone marrow dysfunction, including acute leukemia and myelodysplasia. Therefore, there is a need to identify the subset of patients who might benefit from these drugs.

The mechanism of action of these compounds is related to the inhibition of the nuclear enzyme DNA topoisomerase II (Topo II), although other antitumor mechanisms have also been described. Topoisomerase II is an important enzyme for cell division because it releases torsional stress in double-stranded DNA by inducing transient breaks that are then subsequently resealed. The catalytic activity of Topo II in mammalian cells is mediated by two isoforms [ie, Topo II α (TOP2A) and Topo II β]. In vitro studies have suggested that sensitivity to Topo II inhibitors is dependent on the expression levels of TOP2A gene in breast cancer cells. In conclusion, TOP2A expression in breast cancer was associated with high proliferation and aggressive tumor subtypes and appears to be independent of its amplification status. All of these features should be taken into consideration when assessing the predictive value of TOP2A for anthracycline-based chemotherapy.
on the expression level of TOP2A in target cancer cells. Cells with a low concentration of TOP2A protein are less sensitive to Topo II–inhibiting drugs versus cells containing a high concentration of TOP2A. Interestingly, the TOP2A gene itself is frequently found coamplified with v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) (ERBB2) in human breast cancer cells,11 and several studies12–16 have shown that anthracycline-containing regimens improve survival in women with ERBB2-positive breast cancer.

Numerous retrospective studies have investigated the predictive value of TOP2A using different methods. Some of these approaches have focused on determining TOP2A expression,17,18 whereas others have evaluated TOP2A copy number.19,20 In any case, the results of these studies are contradictory and it is still unclear whether investigating TOP2A provides useful clinical information concerning anthracycline benefit. Current techniques for measuring TOP2A are not standardized, which may account, at least partly, for these apparently contradictory results. In addition, the agreement among techniques and the correlation between TOP2A expression values measured by different methods is also not well established. On the other hand, TOP2A is considered a surrogate marker of cell proliferation and its expression has been associated with high tumor grade21,22 and the absence of hormone receptors,23 suggesting that overexpression of TOP2A could be characteristic of a specific type of breast tumor. Investigation of the predictive significance of TOP2A for anthracycline-containing regimens requires knowing the correlation between different methods and the characterization of TOP2A-expressing tumors to control potential confounding factors.

The aim of this study was to evaluate the status of TOP2A in breast cancer tumors by four different methods [ie, fluorescence in situ hybridization (FISH), gene expression via DNA microarrays, gene expression via real-time PCR (Q-PCR), and immunohistochemistry (IHC)]. We also sought to assess the correlation and agreement among these techniques when classifying the tumors as TOP2A positive or negative. In addition, TOP2A status was correlated to clinical features, such as cell proliferation, hormone receptor status, and breast cancer intrinsic subtypes, that identified many significant correlations.

Material and Methods

Study Population

Tumor biopsy specimens were obtained from a set of 61 pretreated patients diagnosed as having locally advanced breast cancer; these patients participated in a neoadjuvant clinical trial (registered at the following Web site: http://www.clinicaltrials.gov; identifier NCT00123929). The clinical trial was approved by the Hospital Clínico San Carlos Ethics Committee, Madrid, Spain. Briefly, eligibility criteria included the following: women aged between 18 and 78 years; clinical stage IIb, IIIA, or IIIB breast cancer; and palpable breast tumors not amenable to breast-preserving surgery. Before the start of the trial, an informed consent was obtained from every patient. A total of 226 registered patients were enrolled in the trial; 204 underwent a complete evaluation. No significant differences were observed between the subset of 61 patients and the whole cohort of 226 patients. Clinical and pathological characteristics of each of the 61 patients are available in Supplemental Table S1 (at http://ajp.amjpathol.org).

RNA Isolation and Microarray Expression Profiling

Total RNA was extracted from tumor biopsy specimens using a kit (Qiagen RNeasy Mini Kit; Qiagen Inc., Valencia, CA), following the instructions of the manufacturer. The biopsy specimens were obtained before neoadjuvant chemotherapy. To check cellularity, an H&E image was obtained from all tumors; only samples with more than 80% tumor cells were used. The amount of RNA was assessed with a device (Nanodrop ND-1000 UV Spectrophotometer; Thermo Fisher Scientific, Wilmington, DE). RNA integrity was assessed using a kit (RNA 6000 Nano Chip kit), followed by analysis (Bioanalyzer 2100; Agilent Technologies, Santa Clara, CA). Whole human genome oligo 4 × 44 microarrays (Agilent Technologies) were hybridized after low RNA input fluorescence amplification of tumor total RNA, according to the manufacturer’s protocol. Arrays were scanned (GenePix 4000B scanner; Molecular Devices Corporation, Sunnyvale, CA), analyzed using software (GenePix 5.1), and uploaded into a University of North Carolina microarray database, in which a Lowess normalization of the log2 ratio (Cy5/Cy3) intensity values is automatically performed. For all analyses, genes were filtered by requiring the Lowess-normalized intensity values in both channels to be greater than 10; only genes that reported values in 70% or more of the samples were included. The genes were median centered across all samples. Breast cancer subtypes were assigned as described by Parker et al.24 In addition, the recently identified subtype named Claudin-low was assigned using a separate centroid-based predictor25; therefore, tumors were categorized into Luminal A, Luminal B, Basal-like, Her2-enriched, Claudin-low, and Normal-like. The primary microarray data presented in this study are available in the Gene Expression Omnibus database (accession No. GSE21997).

Q-PCR Analysis

Total RNA, 200 ng, was used as a template to obtain first-strand cDNA using a system (SuperScript First-Strand Synthesis System for RT-PCR; Invitrogen, Parsley, UK), following the manufacturer’s instructions. To determine that cDNA was synthesized, the first-strand cDNA was further amplified by conventional PCR using primers for β-actin, as previously described.26 Real-time PCR was performed using gene expression assays (TaqMan; Applied Biosystems, Foster City, CA) and a PCR system (ABI PRISM 7900HT Fast Real Time PCR System; Applied Biosystems). Briefly, 4 μL of
cDNA template was mixed with 1 μL of ×20 TOP2A primers, probes labeled with 5,6 carboxifluoresceina reporter dye (assay Hs00172214_m1), 1 μL of ×20 human β-actin primers, and probes labeled with VIC-reported dye (TaqMan endogenous control, part 4326315E; Applied Biosystems), 10 μL of mix (TaqMan Universal PCR Mastermix), and 4 μL of RNase-free water. Human β-actin served as an endogenous control to normalize the TOP2A mRNA levels in the subsequent quantitative analysis. The PCR conditions were those recommended by the manufacturer. A pool of RNA from 11 breast tissue samples of healthy individuals who underwent cosmetic or plastic surgery was used as a control. Each sample was measured in triplicate. The data were analyzed by the comparative Ct method, in which the amount of replicate. The data were analyzed by the comparative Ct

**IHC and Tumor Grading**

Paraffin-embedded tumor samples from core biopsy specimens were evaluated by IHC analysis for TOP2A (TOP2A-mouse monoclonal antibody Novocasta Leica-TopollA, clone 3F6, 1:40; Leica Microsystems, Wetzlar, Germany); estrogen receptor (ER) (clone 1D5, 1:35; Dako Cytomation, Glostrup, Denmark), progesterone receptor (clone PgR 636, 1:50; Dako Cytomation), and Ki-67 (clone MIB-1, 1:75; Dako Cytomation). After incubation with the primary antibodies, immunohistochemical studies were performed using a Bond-Max immunos- tainer (Vision BioSystems, Hingham, MA) with polymer- defined peroxidase detection.

Because no cutoff for positivity has been validated to define TOP2A overexpression, we analyzed this variable based on a cutoff of 20% or greater (mean value in this study) and median values (10% of stained cells). The Ki-67 positivity was defined as 20% or greater of stained cells because the staining in our normal control breast tissue (from the tissue bank of Hospital Clínico San Carlos) was always lower than this value. The cut points for ER and progesterone receptor positivity were established at 10% or greater of stained cells. All tumors were graded by the study pathologist (JALGA) by using Elston-Ellis histological grading.27

### Measurement of TOP2A and ERBB2 Amplification

The amplification of TOP2A and ERBB2 was measured by FISH. The probes used were as follows: locus-specific identifier TOP2A, labeled in orange; centromere enumeration probe 17, labeled in green; and locus-specific identifier ERBB2 probe, labeled in orange (Vysis-Abbott, Downers Grove, IL). Slides were prepared according to

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>FISH data</th>
<th>Q-PCR data</th>
<th>Microarray data</th>
<th>IHC data</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. of participants (n = 61)</td>
<td>No. of tumors with TOP2A CNAs (n = 15)</td>
<td>TOP2A expression*</td>
<td>P value</td>
</tr>
<tr>
<td>Tumor size (cm)</td>
<td>≤5</td>
<td>24</td>
<td>2</td>
<td>0.03†</td>
</tr>
<tr>
<td></td>
<td>&gt;5</td>
<td>37</td>
<td>13</td>
<td>0.57 (1.7)</td>
</tr>
<tr>
<td>Histological feature</td>
<td>Ductal</td>
<td>48</td>
<td>13</td>
<td>0.87</td>
</tr>
<tr>
<td></td>
<td>Lobular</td>
<td>10</td>
<td>2</td>
<td>0.35 (1.5)</td>
</tr>
<tr>
<td></td>
<td>Other</td>
<td>3</td>
<td>0</td>
<td>0.72 (1.5)</td>
</tr>
<tr>
<td>Stage at diagnosis</td>
<td>II</td>
<td>21</td>
<td>2</td>
<td>0.03†</td>
</tr>
<tr>
<td></td>
<td>IIIA</td>
<td>20</td>
<td>4</td>
<td>0.73 (1.6)</td>
</tr>
<tr>
<td></td>
<td>IIIB</td>
<td>20</td>
<td>9</td>
<td>0.83 (1.8)</td>
</tr>
<tr>
<td>Histological grade</td>
<td>II</td>
<td>40</td>
<td>9</td>
<td>0.76</td>
</tr>
<tr>
<td></td>
<td>III</td>
<td>21</td>
<td>6</td>
<td>0.99 (1.8)</td>
</tr>
<tr>
<td>Ki-67</td>
<td>Low</td>
<td>18</td>
<td>3</td>
<td>0.52</td>
</tr>
<tr>
<td></td>
<td>High</td>
<td>43</td>
<td>12</td>
<td>1.07</td>
</tr>
<tr>
<td>Estrogen receptor</td>
<td>Positive</td>
<td>36</td>
<td>12</td>
<td>0.07</td>
</tr>
<tr>
<td></td>
<td>Negative</td>
<td>25</td>
<td>3</td>
<td>0.95 (1.7)</td>
</tr>
<tr>
<td>Progesterone receptor</td>
<td>Positive</td>
<td>37</td>
<td>10</td>
<td>0.76</td>
</tr>
<tr>
<td></td>
<td>Negative</td>
<td>24</td>
<td>5</td>
<td>0.76 (1.6)</td>
</tr>
<tr>
<td>ERBB2 status</td>
<td>Positive</td>
<td>19</td>
<td>8</td>
<td>0.05†</td>
</tr>
<tr>
<td></td>
<td>Negative</td>
<td>42</td>
<td>7</td>
<td>0.76 (1.7)</td>
</tr>
</tbody>
</table>

CNA, copy number alteration.
*Data are given as the mean (SD).
†Significant difference.
the manufacturer’s instructions for paraffin sections. A positive result was defined as an ERBB2 and TOP2A genes/chromosome 17 ratio of 2.2 or greater (for ERBB2) or greater than 2 (for TOP2A). The cutoff for the deletion was established as a TOP2A gene/chromosome 17 ratio of 0.5 or lower. Images were visualized on a fluorescence microscope and captured on a workstation (MetaSystems, Altlussheim, Germany). A minimum of 100 nuclei were counted per case. All cut points were predefined before the correlations were performed; in all of the cases, the pathologist (JALGA) was blinded from the patient’s identity and outcome.

**Statistical Analysis**

Qualitative variables were summarized by their frequency distribution, and quantitative variables were summarized by their mean ± SD. The continuous values of Q-PCR were log transformed. For qualitative variables, comparison was evaluated by the χ² or Fisher exact test in cases in which more than 25% of the expected values were less than five. The association between the expression of TOP2A, measured by gene expression microarrays or Q-PCR, and other qualitative variables was assessed by t-test. To compare between more than two groups, a one-way analysis of variance was used. The correlation among the quantitative values of TOP2A expression, measured by Q-PCR and gene expression microarrays, was evaluated with simple linear regression analysis. The comparison between TOP2A expression data, assessed by IHC, and gene expression microarrays or Q-PCR was performed using receiver operating characteristic curve analysis. The area under the curve, sensitivity, and specificity were also determined. The adjusted false-positive, false-negative, and error rates of the determined cutoffs were estimated using a bootstrapping method. Simple Cohen’s κ coefficients and percentage agreement with its 95% confidence interval were used to assess the agreement when classifying the tumors as TOP2A positive or TOP2A negative. The strength of agreement is considered to be slight when κ values are between 0.00 and 0.20; fair, 0.21 and 0.40; moderate, 0.41 and 0.60; good, 0.61 and 0.80; and almost perfect, 0.81 and 1.00. All statistical tests were two sided, and P < 0.05 was considered significant. The statistical analysis was performed using software (SPSS 17.0 and R 2.10.1).

**Results**

**Clinicopathological Characteristics of the Study Population**

Table 1 summarizes the pathological characteristics of the 61 tumor samples/patients and the distribution of characteristics by TOP2A status. As shown, TOP2A copy number alterations were significantly associated with tumor size, stage, and ERBB2 amplification status. Interestingly, TOP2A expression, as assessed by Q-PCR or microarray, was not significantly associated with any of these characteristics. On the other hand, TOP2A status, by Q-PCR and gene expression microarrays, was significantly associated with Ki-67 positivity (P = 0.008 and P = 0.005, respectively). Similarly, according to IHC data, TOP2A protein overexpression was more frequent in Ki-67-positive tumors, although Ki-67 positivity was not significantly associated with TOP2A IHC positivity (P = 0.08).

In addition, we found that TOP2A mRNA expression, as assessed by Q-PCR or gene expression microarrays, varied significantly with intrinsic subtype (P < 0.001 in both cases). High-proliferative subtypes, such as Basal-like, Luminal B, and Her2-enriched, expressed higher levels of TOP2A than Luminal A, Claudin-low, or Normal-like tumors (Figure 1A and B). In the same way, according to IHC data, the proportion of TOP2A-positive tumors was statistically different depending on tumor subtype (P = 0.002). As shown in Figure 1C, Basal-like, Her2-enriched, and Luminal B tumors had the most TOP2A-positive tumors, whereas Luminal A tumors were mostly TOP2A negative and all Normal-like tumors were TOP2A negative. Therefore, TOP2A expression can be considered a proliferative marker that is highly characteristic of the rapidly growing tumor subtypes. Finally, we observed that TOP2A copy number alterations occurred in Luminal A, Luminal B, Her2-enriched, and Claudin-low subtypes; no alterations were found in Basal-like and Normal-like tumors (Figure 1D).

**Correlation Between TOP2A Status Assessed by Q-PCR, Gene Expression Array, and IHC**

The TOP2A expression values measured by Q-PCR and gene expression microarrays significantly correlated with each other (Pearson correlation coefficient, 0.816; 95% confidence interval, 0.71 to 0.89; P = 1.2 × 10⁻¹⁵) (Figure 2). In addition, tumors with positive TOP2A expression by IHC had relatively higher mean levels of TOP2A expression, as measured by Q-PCR (P = 0.002) or gene expression microarrays (P < 0.001).

To demonstrate the concordance of TOP2A expression status, determined by these techniques, we performed receiver operating characteristic curve analysis to assess how TOP2A gene expression by Q-PCR or microarrays can predict TOP2A-positive status by IHC. For Q-PCR, the area under the curve was 0.741 (sensitivity, 80%; specificity, 72%; best cutoff value, 1.04; adjusted error rate, 27%; adjusted false-positive rate, 23%; adjusted false-negative rate, 30%); for gene expression microarrays, the area under the curve was 0.791 (sensitivity, 100%; specificity, 53%; best cutoff value, 0.48; adjusted error rate, 30%; adjusted false-positive rate, 4%; adjusted false-negative rate, 49%) (Figure 3).

**TOP2A Copy Number Alteration and TOP2A Expression**

The TOP2A was amplified in 13 cases (21.3%) and deleted in 2 cases (3.3%). Unlike RNA and protein levels, no significant association was observed between TOP2A
copy number alterations and the expression of the gene measured by Q-PCR or gene expression microarrays. In addition, we did not find agreement between IHC and FISH when assessing TOP2A status in tumor samples ($\kappa = 0.134$, $P = 0.26$) (Table 2).

**Discussion**

In this study, TOP2A gene expression, as assessed by DNA microarray or Q-PCR, was significantly associated with Ki-67 IHC positivity. When TOP2A was assessed by IHC, a similar tendency was observed. Taken together, these data suggest that TOP2A expression across all breast cancers is likely a proliferation marker, which is concordant with previous reports about breast cancer and tumor types. Consistent with these data, we found higher TOP2A gene expression in highly proliferative subtypes, such as Basal-like, Luminal B, and Her2-enriched tumors, when compared with Luminal A, Normal-like, and Claudin-low tumors. Therefore, tumor proliferation may have a confounding effect on the predictive value of TOP2A and, therefore, TOP2A expression may possibly need to be adjusted for Ki-67 or other proliferative markers.
There is growing evidence supporting that breast cancer is a heterogeneous disease, rather than a single disease; and breast cancer subtypes have specific clinicopathological characteristics with different prognoses. The relative benefit of anthracyclines has not been tested for each specific breast cancer molecular subtype, although therapeutic outcome might be affected by molecular subtype. Different results among researchers who have assessed the predictive value of TOP2A expression might be, in part, because of different proportions of breast cancer subtypes between study populations; we demonstrated that TOP2A expression is substantially different across the known subtypes.

In our study, TOP2A amplification was associated with tumor size, stage, and ERBB2 positivity. Interestingly, none of these characteristics was associated with TOP2A expression. This might suggest that TOP2A protein–over-expressing tumors and tumors with TOP2A copy number alterations might be biologically different. Indeed, we found that the distribution of TOP2A-amplified tumors among subtypes is different and that the protein expression is also uniquely different; thus, it is not surprising to find that the FISH and IHC data are not that highly correlated. The expression of TOP2A has been extensively studied in human breast cancers by different methods. However, the correlation between techniques has been scarcely reported. As expected, our results showed a good correlation among Q-PCR and gene expression microarrays (Pearson correlation coefficient, 0.816).

A threshold value for TOP2A expression that could define subgroups associated with treatment outcome remains to be established. Some researchers have used an arbitrary IHC cutoff of greater than 10%, whereas others have used a 25% cutoff. We used a cutoff of 20% because staining in our control healthy breast tissue was always lower than this value; however, similar results were obtained when considering the cutoff of 10% (data not shown). We found that both microarrays and Q-PCR predicted fairly well the TOP2A expression values measured by IHC. In addition, our results showed a significant association between TOP2A mRNA and protein levels. However, IHC is potentially a more subjective technique and may have a lower precision when assessing the status of TOP2A relative to Q-PCR. Interestingly, no association between TOP2A copy number alterations and the expression of the gene was observed, which is in agreement with previous reports.

Because TOP2A is considered the molecular target of anthracyclines, the predictive value of this gene in patients with breast cancer has been widely studied. Several retrospective studies have shown that ERBB2-positive tumors are rather sensitive to anthracyclines. In addition, amplification of ERBB2 is variable in size. Some flanking genes in the 17q12-q21 region, such as TOP2A, are frequently either coamplified or deleted in breast cancers with ERBB2 amplification. Because of this coincidence, many researchers have hypothesized that TOP2A amplification might become the gold standard predictive factor for anthracyclines, rather than ERBB2; and many retrospective studies have been conducted to assess its predictive value. However, although several studies have shown that TOP2A alterations are associated with an increased responsiveness to anthracycline-containing regimens, others have been inconclusive.

Our data suggest that TOP2A amplification and TOP2A overexpression are indicative of different biological processes because these two events are not associated and are characteristic of different tumor subtypes. For example, Basal-like tumors typically overexpressed TOP2A protein and/or mRNA, but no Basal-like tumor had TOP2A DNA copy number changes. This might suggest that the predictive value of TOP2A copy number may not be because of a TOP2A protein function. Rather, it may be indicative of some other biological process or genomic aberration that could be characteristic of ERBB2-amplified tumors because TOP2A amplification occurs almost exclusively within ERBB2-amplified tumors. In support of this hypothesis, a previous study performed in a cohort of 245 patients, found that TOP2A amplification predicted benefit from adjuvant anthracyclines only in the subset of ERBB2-positive breast cancer but failed to predict response when the entire population of the study was considered. Similarly, the TOP trial showed that TOP2A am-

Table 2. The TOP2A-Positive and TOP2A-Negative Tumors According to FISH and IHC Results

<table>
<thead>
<tr>
<th>FISH results</th>
<th>IHC results</th>
<th>κ (P) value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive</td>
<td>8 (13)</td>
<td>7 (11)</td>
</tr>
<tr>
<td>Negative</td>
<td>17 (28)</td>
<td>29 (48)</td>
</tr>
</tbody>
</table>

Data are given as number (percentage) of 61 tumors unless otherwise indicated.

*Cohen’s κ coefficient for agreement between FISH and IHC results.
plification, which was always associated with \textit{ERBB2} amplification, predicted benefit from regimens containing anthracyclines in ER-negative tumors.\textsuperscript{46} In both studies, \textit{TOP2A} expression did not correlate with treatment outcome. Contrary to these results, we recently observed that \textit{TOP2A} expression is predictive of response to a single agent, doxorubicin, but not \textit{TOP2A} amplification.\textsuperscript{47} Because the target of anthracyclines is the \textit{TOP2A} protein, not the gene, it seems that the study of the expression (RNA and protein) might predict more accurately the treatment outcome with anthracyclines than \textit{TOP2A} copy number alterations (amplification or deletion); further studies on this point are clearly warranted.

In summary, \textit{TOP2A} copy number alterations do not correlate with gene expression in breast cancers, and the expression of the gene/protein varies significantly depending on the tumor subtype and proliferation status. These facts could explain, in part, the previously reported discrepancies regarding the predictive value of \textit{TOP2A} for anthracycline-based chemotherapy regimens.

\textbf{References}


47. Chia SK, Ung K, Bramwekk VH, Tu D, Perou CM, Ellis MJ, Bernad DS, Vickery T, Shepherd LE, Nielsen TO: Prognostic and Predictive impact of biologic classification by qRT-PCR with a 50-gene subtype predictor (PAM50) for adjuvant tamoxifen in premenopausal breast cancer: Results from the NCIC CTG MA.12 randomized trial. Abstract 508. Presented at the ASCO Annual Meeting, June 4–8, 2010, Chicago, IL